Contributions
Abstract: EP1407
Type: ePoster
Abstract Category: Clinical aspects of MS - Economic burden
Aim: To study the use of hospitalization and emergency department (ED) resources of patients with Multiple Sclerosis (MS) followed up in an MS Unit.
Patients and methods: All the patients visited in our MS Unit during 2014 fulfilling Mc Donald 2010 criteria were retrospectively selected and their hospital electronic medical records were searched for hospital admissions and ED visits during 2014 and 2015. Our sanitary district comprises 201816 inhabitants and our center has the only hospital ED. Hospitalizations and ED consultations were classified as directly related to MS (relapses, adverse events), possibly related (decubitus, deep venous thrombosis) or non-related with MS.
Results: 181 patients were included (mean age 50.5 years; median irreversible EDSS 2.0; mean disease duration 17.6 years, 69.6% women, 56.5% under disease modifying treatment). They represent nearly 100% of the expected population prevalence. 27 patients (14.9%) experienced 34 hospitalizations during the study period (annualized hospitalization ratio (AHR) 9.4%). 20 hospitalizations were recorded (10.9%) from 16 patients during 2014 (4 possibly related to MS and 4 directly related) and 14 hospitalizations (7.7%) from 14 patients during the second year (6 possibly related and 2 related to MS). The AHR related to MS was 4.4%. Younger age and progressive MS were independent risk factors for hospitalization.
71 patients made 156 ED consultations (EDC) during these two years. Annualized EDC ratio was 43.0%. Directly or possibly related to MS EDC represented only the 25.6% of ED consultations. Annualized EDC ratio for MS related events was 11%. Seven out of 40 EDC related to MS resulted in hospitalization (17.5%). Older age at onset, shorter disease duration and progressive MS were independent factors for an increased risk of EDC.
Conclusion: Progressive MS patients need more healthcare resources. MS Units can help to limit the utilization of other healthcare resources such as hospitalization and ED consultations.
Disclosure:
Antonio Martínez Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Lucia Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Elisabeth Matas Martín received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Laura Bau Vila received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
PIlar Fernandez nothing to disclose
Isabel Leon received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Maite Anguix received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Sergio Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Abstract: EP1407
Type: ePoster
Abstract Category: Clinical aspects of MS - Economic burden
Aim: To study the use of hospitalization and emergency department (ED) resources of patients with Multiple Sclerosis (MS) followed up in an MS Unit.
Patients and methods: All the patients visited in our MS Unit during 2014 fulfilling Mc Donald 2010 criteria were retrospectively selected and their hospital electronic medical records were searched for hospital admissions and ED visits during 2014 and 2015. Our sanitary district comprises 201816 inhabitants and our center has the only hospital ED. Hospitalizations and ED consultations were classified as directly related to MS (relapses, adverse events), possibly related (decubitus, deep venous thrombosis) or non-related with MS.
Results: 181 patients were included (mean age 50.5 years; median irreversible EDSS 2.0; mean disease duration 17.6 years, 69.6% women, 56.5% under disease modifying treatment). They represent nearly 100% of the expected population prevalence. 27 patients (14.9%) experienced 34 hospitalizations during the study period (annualized hospitalization ratio (AHR) 9.4%). 20 hospitalizations were recorded (10.9%) from 16 patients during 2014 (4 possibly related to MS and 4 directly related) and 14 hospitalizations (7.7%) from 14 patients during the second year (6 possibly related and 2 related to MS). The AHR related to MS was 4.4%. Younger age and progressive MS were independent risk factors for hospitalization.
71 patients made 156 ED consultations (EDC) during these two years. Annualized EDC ratio was 43.0%. Directly or possibly related to MS EDC represented only the 25.6% of ED consultations. Annualized EDC ratio for MS related events was 11%. Seven out of 40 EDC related to MS resulted in hospitalization (17.5%). Older age at onset, shorter disease duration and progressive MS were independent factors for an increased risk of EDC.
Conclusion: Progressive MS patients need more healthcare resources. MS Units can help to limit the utilization of other healthcare resources such as hospitalization and ED consultations.
Disclosure:
Antonio Martínez Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Lucia Romero-Pinel received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Elisabeth Matas Martín received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Laura Bau Vila received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
PIlar Fernandez nothing to disclose
Isabel Leon received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Maite Anguix received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono
Sergio Martínez-Yélamos received research support, funding for travel and congress expenses and honoraria from speaking engagements from Biogen Idec, Teva Pharmaceutical Industries LTD, Sanofi-Aventis, Novartis, Bayer HealthCare Pharmaceuticals and Merck Serono